Dr. Flora Vaccarino graduated in Medicine at Padua University in Italy and studied neuropharmacology and cell biology at NIH as a research fellow before starting her Residency in Psychiatry at Yale University. After her residency, she studied developmental biology and genetics and was appointed Assistant Professor at Yale University. Her interests are the development of the mammalian the cerebral cortex, basal ganglia and connected forebrain regions as well as the regulation of neural stem cells in both embryonic and postnatal periods. Her lab has been investigating how genetic (i.e., tyrosine growth factor receptors like Fibroblast Growth Factors) and epigenetic factors (i.e., perinatal hypoxia, environmental enrichment) affect the proliferation the maturation of neural progenitor cells in mouse models. Recently she has been exploring how induced pluripotent stem cells (iPSCs) can be used to model developmental neuropsychiatric disorders including autism and Rett syndrome. With a group of colleagues, Dr. Vaccarino, now a full Professor at Yale University School of Medicine, founded in 2009 the “Program in Neurodevelopment and Regeneration” (https://medicine.yale.edu/neurodevelopment/), a collaborative interdepartmental program at Yale University that is leading interdisciplinary studies on iPSCs, neural stem cells and human development.Dr. Vaccarino is a Fellow of American Association for the Advancement of Science and a member of the PsychENCODE and the Brain Somatic Mosaicism Consortia.
Specialty Stem Cell Treatments
MD Stem Cells is the sponsor of specialty clinical studies involving ophthalmology, neurology and spinal cord injury. Our success stems from years of effort first in Europe and, beginning in 2013, with US-based, FDA compliant, IRB approved and NIH registered studies. MD Stem Cells provides the only stem cell treatments in ophthalmology with medical journal published, statistically significant results. That means eligible patients can enroll in a study with scientifically proven results right now. We use only adult, bone marrow-derived stem cells – never adipose, fat, or embryonic derived cells. Our proprietary approaches maximize yield and effectiveness. With hundreds of patients having participated and significant numbers having meaningful improvements, we hope you take a careful look at our experience and results.
We are a consultancy providing information, education, facilitation, and access to advanced stem cell treatments. We act as Sponsor and Dr. Levy is Study Director for clinical trials involving bone marrow stem cells in ophthalmology, neurology and spinal cord injury.
Many diseases and injuries have no medical approaches that can recover the function that has been lost. For many patients their first encounter with a disease or injury results in the realization that they are on their own- that the medical and pharmaceutical community, for all their success in certain diseases, can offer them little or nothing. Focused on clinical and translational research, we aim to find new and innovative treatments to mitigate diseases and injuries. We are on a journey to treat within clinical studies and publish our results in order to change the standard of care patients are offered. Patients choosing to participate in our studies must understand that results cannot be predicted for individual patients. Even in diseases where we have shown statistically significant benefit, there is no guarantee that a particular patient will benefit from treatment.
Stem cells are a new and innovative form of treatment. Research has shown that these cells can help form and repair tissues all over the body. We believe strongly that bone marrow-derived stem cells have important benefits over other types of stem cells including a 30x better ability to travel through the lungs to the capillary beds of the brain, eyes and spinal cord. While the pharmaceutical industry continues efforts to create cell-based products, we believe that harnessing the human body’s own repair mechanisms can produce important benefits now.